101
|
Gilmore-Bykovskyi AL, Block LM, Walljasper L, Hill NL, Gleason CE, Shah M. P3‐281: UNSTRUCTURED CLINICAL DOCUMENTATION DESCRIBING SYMPTOMS OF COGNITIVE IMPAIRMENT IN THE ELECTRONIC HEALTH RECORD. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
102
|
Wyman MF, Schmidt J, Flood M, Dolwick P, Gleason CE. P2‐530: A WHOLE‐FACILITY APPROACH: IMPLEMENTING AN INNOVATIVE MODEL OF A ‘DEMENTIA FRIENDLY HOSPITAL’ AT THE MADISON, WI, VA MEDICAL CENTER. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
103
|
Mora Pinzon MC, Krainer J, Pophal H, Houston S, O'Toole Smith K, Green-Harris G, Norris N, Kowalski K, Clark LR, Gleason CE, Hermann BP, Johnson SC, Mahoney J, Carlsson CM. P3‐502: MEMORY CLINIC NETWORK: CHALLENGES AND OPPORTUNITIES FOR RESEARCH. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
104
|
Zuelsdorff M, Okonkwo OC, Shouel HL, Benton SF, Wyman MF, Nystrom NC, Johnson SC, Gleason CE. P4‐376: PSYCHOSOCIAL PREDICTORS OF HIPPOCAMPAL VOLUME AND COGNITION AMONG AFRICAN AMERICAN AND WHITE OLDER ADULTS AT RISK FOR ALZHEIMER'S DISEASE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.07.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
105
|
Van Hulle CA, Lazar KK, Ma Y, Johnson SC, Clark LR, Zetterberg H, Blennow K, Bendlin BB, Okonkwo OC, Gleason CE, Chappell RJ, Jacobson LH, Blazel H, Cole A, Asthana S, Carlsson CM. P1‐248: LATENT PROFILES DERIVED FROM ATN RELATED CSF BIOMARKERS. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
106
|
Russek NS, Gepner AD, Korcarz CE, Berman SE, Lazar KK, Ma Y, Hoffman CA, Rivera LA, Austin B, Chappell RJ, Clark LR, Oh JM, Illingworth C, Jacobson L, Blazel H, Gleason CE, Bendlin BB, Asthana S, Turski P, Johnson SC, Stein JH, Wieben O, Carlsson CM. P4‐304: RELATIONSHIP BETWEEN AORTIC AUGMENTATION INDEX BY RADIAL ARTERY TONOMETRY AND CEREBRAL PULSATILITY INDEX IN INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.07.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
107
|
Gleason CE, Morgan KN, Dowling M. F2‐01‐03: AN UPDATE ON MENOPAUSAL HORMONE THERAPY TRIALS. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
108
|
Beeri MS, Lin H, Ravona-Springer R, Sano M, Bendlin BB, Gleason CE, Guerrero-Berroa E, Soleimani L, Launer LJ, Levy A. O1‐14‐02: THE HAPTOGLOBIN 1‐1 GENOTYPE IS ASSOCIATED WITH COGNITIVE FUNCTION AND DECLINE IN AFRICAN AMERICAN PERSONS WITH TYPE 2 DIABETES: THE ACCORD‐MIND STUDY. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.3048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
109
|
Zuelsdorff M, Gleason CE, Kind AJ, Koscik RL, Wyman MF, Benton SF, Johnson SC, Okonkwo OC. P3‐580: INFORMAL CAREGIVING AND COGNITIVE HEALTH: SOCIOCULTURAL DIFFERENCES AMONG MIDDLE‐AGED AND OLDER ADULTS AT RISK FOR ALZHEIMER'S DISEASE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
110
|
Ma Y, Chappell RJ, Clark LR, Wahoske ML, Johnson SC, Carlsson CM, Chin NA, Asthana S, Gleason CE. P2‐480: LATENT FACTOR STRUCTURE AND MEASUREMENT INVARIANCE OF THE NIH TOOLBOX COGNITION BATTERY IN A SAMPLE FROM THE WISCONSIN ALZHEIMER'S DISEASE RESEARCH CENTER. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
111
|
Carter FP, Benton SF, Edwards DF, Blazel H, Harris BL, Lucille J, Smith T, Green-Harris G, Carlsson CM, Johnson SC, Gleason CE. P2‐524: KEY ELEMENTS SUPPORTING RECRUITMENT AND RETENTION OF UNDERREPRESENTED GROUPS INTO RESEARCH: OUR EXPERIENCE IN THE AFRICAN AMERICAN COMMUNITY. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
112
|
Cole A, Van Hulle CA, Chin NA, Blazel H, Clark LR, Lazar KK, Johnson SC, Bendlin BB, Okonkwo OC, Gleason CE, Edwards DF, Wahoske ML, Blazel M, Asthana S, Carlsson CM. P3‐271: LUMBAR PUNCTURE SIDE EFFECT RATES IN A RESEARCH SETTING. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1631] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
113
|
Clark LR, Johnson HM, Berman SE, Norton DL, Carter FP, Harris BL, Benton SF, Zuelsdorff M, Nystrom NC, Wyman MF, Bendlin BB, Carlsson CM, Wieben O, Turski P, Rowley HA, Asthana S, Johnson SC, Gleason CE. P1‐456: ASSOCIATION OF CARDIOVASCULAR RISK FACTORS WITH MICRO‐ AND MACROVASCULAR CEREBRAL FUNCTION IN WHITES AND AFRICAN AMERICANS. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
114
|
Wyman MF, Norton DL, Ma Y, Burke SL, Walaszek A, Umucu E, Zuelsdorff M, Nystrom NC, Carlsson CM, Johnson SC, Asthana S, Gleason CE. P1‐365: THE ASSOCIATION OF DEPRESSIVE SYMPTOMS, APATHY, AND ANTIDEPRESSANT USE WITH INCIDENT MCI AND DEMENTIA IN THE NACC DATASET. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
115
|
Benton SF, Kaseroff A, Gunn W, Carter FP, Hills O, Phillips B, Tansey T, Rosenthal D, Chan F, Gleason CE. P3‐626: THE LIVING WELL TOGETHER PROGRAM: A QUALITATIVE ANALYSIS OF A HEALTH SELF‐MANAGEMENT PROGRAM FOR AGING AFRICAN AMERICANS WITH CHRONIC ILLNESS. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
116
|
Kantarci K, Tosakulwong N, Lesnick TG, Zuk SM, Lowe VJ, Fields JA, Gunter JL, Senjem ML, Settell ML, Gleason CE, Shuster LT, Bailey KR, Dowling NM, Asthana S, Jack CR, Rocca WA, Miller VM. Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology 2018; 90:e1404-e1412. [PMID: 29661902 PMCID: PMC5902783 DOI: 10.1212/wnl.0000000000005325] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 01/18/2018] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVE The effects of 2 frequently used formulations of menopausal hormone therapy (mHT) on brain structure and cognition were investigated 3 years after the end of a randomized, placebo-controlled trial in recently menopausal women with good cardiovascular health. METHODS Participants (aged 42-56 years; 5-36 months past menopause) were randomized to one of the following: 0.45 mg/d oral conjugated equine estrogen (oCEE); 50 μg/d transdermal 17β-estradiol (tE2); or placebo pills and patch for 4 years. Oral progesterone (200 mg/d) was given to mHT groups for 12 days each month. MRIs were performed at baseline, at the end of 4 years of mHT, and 3 years after the end of mHT (n = 75). A subset of participants also underwent Pittsburgh compound B-PET (n = 68). RESULTS Ventricular volumes increased more in the oCEE group compared to placebo during the 4 years of mHT, but the increase in ventricular volumes was not different from placebo 3 years after the discontinuation of mHT. Increase in white matter hyperintensity volume was similar in the oCEE and tE2 groups, but it was statistically significantly greater than placebo only in the oCEE group. The longitudinal decline in dorsolateral prefrontal cortex volumes was less in the tE2 group compared to placebo, which correlated with lower cortical Pittsburgh compound B uptake. Rates of global cognitive change in mHT groups were not different from placebo. CONCLUSIONS The effects of oCEE on global brain structure during mHT subside after oCEE discontinuation but white matter hyperintensities continue to increase. The relative preservation of dorsolateral prefrontal cortical volume in the tE2 group over 7 years indicates that mHT may have long-term effects on the brain. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that the rates of change in global brain volumes and cognitive function in recently menopausal women receiving mHT (tE2 or oCEE) were not significantly different from women receiving placebo, as measured 3 years after exposure to mHT.
Collapse
|
117
|
Gleason CE, Norton D, Anderson ED, Wahoske M, Washington DT, Umucu E, Koscik RL, Dowling NM, Johnson SC, Carlsson CM, Asthana S. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker. J Alzheimers Dis 2018; 61:79-89. [PMID: 29125485 PMCID: PMC5714663 DOI: 10.3233/jad-170498] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Alzheimer's disease (AD) biomarkers are emerging as critically important for disease detection and monitoring. Most biomarkers are obtained through invasive, resource-intense procedures. A cognitive marker, intra-individual cognitive variability (IICV) may provide an alternative or adjunct marker of disease risk for individuals unable or disinclined to undergo lumbar puncture. OBJECTIVE To contrast risk of incident AD and mild cognitive impairment (MCI) associated with IICV to risk associated with well-established biomarkers: cerebrospinal fluid (CSF) phosphorylated tau protein (p-tau181) and amyloid-β 42 (Aβ42) peptide. METHODS Dispersion in cognitive performance, IICV, was estimated with a published algorithm, and included Trail Making Test A and B, Rey Auditory Verbal Learning Test (RAVLT), and the American National Adult Reading Test (ANART). CSF biomarkers were expressed as a ratio: p-tau181/Aβ42, wherein high values signified pathognomonic profiles. Logistic regression models included longitudinal data from 349 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants who completed lumbar puncture. All subjects were cognitively healthy (n = 105) or diagnosed with MCI (n = 244) at baseline. We examined odds of conversion associated with baseline elevations in IICV and/or ratio of CSF p-tau181/Aβ42. RESULTS When included in models alone or in combination with CSF p-tau181/Aβ42, one standard IICV unit higher was associated with an estimated odds ratio for incident AD or MCI of 2.81 (95% CI: 1.83-4.33) in the most inclusive sample, and an odds ratio of 3.41 (95% CI: 2.03-5.73) when restricted to participants with MCI. Iterative analyses suggested that IICV independently improved model fit even when individual index components were included in comparative models. CONCLUSIONS These analyses provide preliminary support for IICV as a marker of incident AD and MCI. This easily-disseminated, non-invasive marker compared favorably to well-established CSF biomarkers.
Collapse
|
118
|
Hoscheidt SM, Starks EJ, Oh JM, Zetterberg H, Blennow K, Krause RA, Gleason CE, Puglielli L, Atwood CS, Carlsson CM, Asthana S, Johnson SC, Bendlin BB. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. J Alzheimers Dis 2017; 52:1373-83. [PMID: 27079723 DOI: 10.3233/jad-160110] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND Type 2 diabetes is associated with an increased risk for Alzheimer's disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline. OBJECTIVE We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOEɛ4 carriage would be associated with greater CSF AD pathology and poor memory performance. METHODS Cognitively asymptomatic middle-aged adults (N = 70, mean age = 57.7 years) from the Wisconsin Alzheimer's Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-β protein precursor β (sAβPPβ), amyloid-β42 (Aβ42), and phosphorylated tau (P-tau181) were examined with respect to HOMA-IR and APOEɛ4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOEɛ4 status. RESULTS Higher HOMA-IR was associated with higher sAβPPβ and Aβ42 . APOEɛ4 carriers had significantly higher levels of sAβPPα, sAβPPβ, and P-tau181/Aβ42 compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance. CONCLUSION Overall, the findings suggest that IR and APOEɛ4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD.
Collapse
|
119
|
Koscik RL, Johnson SC, Norton DL, Clark LR, Green‐Harris G, Hermann BP, Asthana S, Edwards DF, Carlsson CM, Gleason CE. [P4–286]: A COMPARISON OF METHODS TO MEASURE INTRA‐INDIVIDUAL COGNITIVE VARIABILITY IN NON‐HISPANIC WHITES AND AFRICAN AMERICANS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP). Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
120
|
Dowling M, Miller VM, Jack CR, Gunter JL, Shuster LT, Zuk SM, Bailey KR, Gleason CE, Kantarci K. [P3–021]: THE ROLE OF CARDIOVASCULAR HEALTH IN MODERATING THE EFFECTS OF POSTMENOPAUSAL HORMONE THERAPY ON NEUROIMAGING OUTCOMES. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
121
|
Koscik RL, Clark LR, Mueller KD, Hermann BP, Chappell RJ, Gleason CE, Johnson SC. [P2–471]: LONGITUDINAL NORMS FOR MID‐LIFE COGNITIVE PERFORMANCE: IDENTIFYING ABNORMAL WITHIN‐PERSON CHANGES IN WRAP. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
122
|
Carter FP, Blazel H, Gleason CE, Harris BL, Asthana S, Edwards DF. [O3–02–02]: A NOVEL PARTICIPANT‐CENTERED APPROACH TO RETENTION: THE WISCONSIN ADRC RENTENTION PROGRAM. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
123
|
Carlsson CM, Johnson SC, Bendlin BB, Berman SE, Clark LR, Zetterberg H, Blennow K, Lazar KK, Okonkwo OC, Gleason CE, Asthana S. [O3–10–02]: LONGITUDINAL CSF BIOMARKER CHANGES IN MIDDLE‐AGED ADULTS AT RISK FOR AD: THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION (WRAP) AND WISCONSIN ADRC COHORTS. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.358] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
124
|
Benton SF, Kaseroff A, Jacobson N, Mahr M, Gunn W, Chan F, Edwards DF, Gleason CE. [P4–378]: A MIXED METHODS ANALYSIS OF SOCIAL COGNITIVE FACTORS INFLUENCING AFRICAN AMERICANS’ INTENTION TO BE SCREENED FOR MILD COGNITIVE IMPAIRMENT. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
125
|
Kind AJ, Bendlin BB, Kim AJ, Koscik RL, Buckingham WR, Gleason CE, Blennow K, Zetterberg H, Carlsson CM, Johnson SC. [O1–04–03]: NEIGHBORHOOD SOCIOECONOMIC CONTEXTUAL DISADVANTAGE, BASELINE COGNITION AND ALZHEIMER's DISEASE BIOMARKERS IN THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION (WRAP) STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|